The Vitamin C Level in Cases with Hematological Malignancies

Öz

Background: Oxidative stress plays a significant role in the pathogenesis of hematological malignan-cies. Vitamin C, known for its antioxidant properties, has garnered attention in this context. There-fore, we investigated vitamin C levels in patients with hematological malignancies and evaluated the relationship between vitamin C levels and response to treatment. Materials and Methods: Our study examined 150 cases of hematological malignancies and 30 he-althy cases. The vitamin C levels of patients with hematological malignancies were compared with those of the healthy group. Results: Vitamin C levels in cases of acute myeloblastic leukemia (n=30) (p<0.001), acute lympho-blastic leukemia (n=30) (p<0.001), Hodgkin lymphoma (n=30) (p<0.001), diffuse large B-cell lympho-ma (n=30) (p<0.001), and multiple myeloma (n=30) (p<0.001) were significantly lower compared to healthy individuals. There was a significant relationship between vitamin C levels and the response to treatment in cases with acute myeloblastic leukemia, acute lymphoblastic leukemia, Hodgkin lymphoma, diffuse large B-cell lymphoma, and multiple myeloma (p=0.020, p=0.020, p=0.040, p<0.001, p<0.001, respectively). In Hodgkin and non-Hodgkin lymphoma cases, a negative correla-tion was found between vitamin C levels and LDH and beta-2 microglobulin levels (p=0.001; p=0.008; p=0.017; p=0.019, respectively). Conclusions: Our study underscores the lower levels of vitamin C in patients with hematological malignancies compared to healthy individuals. Furthermore, the findings suggest that vitamin C levels could serve as a potential biomarker for predicting the response to treatment in these cases.

Anahtar Kelimeler

• Hematological malignancies
• Vitamin C
• Oxidative stress

Hematolojik Maligniteli Olgularda C Vitamini Seviyesi

Öz

Amaç: Oksidatif stres, hematolojik malignitelerin patogenezinde önemli bir rol oynamaktadır. Anti-oksidan özellikleri ile bilinen C vitamini, bu bağlamda dikkat çekmektedir. Bu nedenle, çalışmamız hematolojik malignitelerde C vitamini seviyelerini araştırmayı ve C vitamini düzeyi ile tedaviye yanıt arasındaki ilişkiyi değerlendirmeyi amaçlamıştır. Materyal ve Metod: Çalışmamızda 150 hematolojik malignite vakası ve 30 sağlıklı vaka incelendi. Hematolojik malignite vakalarının C vitamini seviyeleri, sağlıklı grup ile karşılaştırıldı. Bulgular: Akut miyeloblastik lösemi (n=30) (p<0.001), akut lenfoblastik lösemi (n=30) (p<0.001), Hodgkin lenfoma (n=30) (p<0.001), diffüz büyük B-hücreli lenfoma (n=30) (p<0.001) ve multipl miye-lom (n=30) (p<0.001) vakalarında C vitamini seviyeleri, sağlıklı bireylerle karşılaştırıldığında anlamlı derecede düşüktü. Akut miyeloblastik lösemi, akut lenfoblastik lösemi, Hodgkin lenfoma, diffüz büyük B-hücreli lenfoma ve multipl miyeloma vakalarında C vitamini seviyeleri ile kemoterapiye yanıt arasında anlamlı bir ilişki bulundu (sırasıyla p=0.020, p=0.020, p=0.040, p<0.001, p<0.001). Hodgkin lenfoma ve non-Hodgkin lenfoma vakalarında, C vitamini seviyeleri ile laktat dehidrogenaz ve beta-2 mikroglobulin seviyeleri arasında negatif bir korelasyon bulundu (sırasıyla r=-0.59, p=0.001; r=-0.47, p=0.008; r=-0.43, p=0.017; r=-0.42, p=0.019). Sonuç: Çalışmamız, hematolojik malignitelerde sağlıklı bireylerle karşılaştırıldığında C vitamini sevi-yelerinin daha düşük olduğunu vurgulamaktadır. Ayrıca, bulgular, C vitamini seviyelerinin bu vakalar-da kemoterapiye yanıtı öngörmek için potansiyel bir biyobelirteç olarak hizmet edebileceğini öner-mektedir.

Anahtar Kelimeler

• : Hematolojik maligniteler
• C vitamini
• Oksidatif stres

Kaynakça

1. 1. Imbesi S, Musolino C, Allegra A, Di Salvo E, Aragona CO, Bongiovanni A, et al. Oxidative stress in oncohematologic diseases: an update. Expert Rev Hematol. 2013;6(3):317-25.
2. 2. Singh RK, Tripathi AK, Tripathi P, Singh S, Singh R, Ahmad R. Studies on biomarkers for oxidative stress in patients with chronic myeloid leukemia. Hematol Oncol Stem Cell Ther. 2009;2:285–288
3. 3. Zhang J, Wang X, Vikash V, Smith A, Johnson B, Williams C, et al. ROS and ROS-mediated cellular signaling. Oxid Med Cell Longev. 2016;2016:4350965
4. 4. Cheng D, Zhao L, Xu Y, Lee S, Kim D, Park E, et al. K-Ras promotes the non-small lung cancer cells survival by coope-rating with sirtuin 1 and p27 under ROS stimulation. Tumour Biol. 2015;36:7221–7232.
5. 5. Weyemi U, Lagente-Chevallier O, Boufraqech M, Patel K, Garcia-Ruiz C, Lee J, et al. ROS-generating NADPH oxidase NOX4 is a critical mediator in oncogenic H-Ras-induced DNA damage and subsequent senescence. Oncogene. 2012;31:1117–1129.
6. 6. Sayre LM, Lin D, Yuan Q, Zhu X, Tang X. Protein adducts generated from products of lipid oxidation: focus on HNE and one. Drug Metab Rev. 2006;38:651–675.
7. 7. Ahmad R, Tripathi AK, Tripathi P, Singh S, Singh R, Singh RK. Malondialdehyde and protein carbonyl as biomarkers for oxidative stress and disease progression in patients with chronic myeloid leukemia. In Vivo. 2008;22:525–528.
8. 8. Al-Gayyar MMH, Eissa LA, Rabie AM, El-Gayar AM. Measu-rements of oxidative stress status and antioxidant activity in chronic leukaemia patients. J. Pharm. Pharmacol. 2007;59:409–417

9. 9. Zima T, Spicka I, Stípek S, Nováková O, Novák F, Novotný L, et al. Antioxidant enzymes and lipid peroxidation in patients with multiple myeloma. Neoplasma. 1996;43:69–73.
10. 10. Bur H, Haapasaari KM, Turpeenniemi-Hujanen T, Soini Y, Karihtala P, Leppä S, et al. Oxidative stress markers and mi-tochondrial antioxidant enzyme expression are increased in aggressive Hodgkin lymphomas. Histopathology. 2014;65:319–327
11. 11. Iqbal K, Khan A, Ali Khan Khattak MM. Biological significan-ce of ascorbic acid (Vitamin C) in human health. A review. Pakistan Journal of Nutrition. 2004;3:5-13
12. 12. Drouin G, Godin JR, Pagé B. The genetics of Vitamin C loss in vertebrates. Current Genomics. 2011;12:371-378.
13. 13. Levine M. New concepts in the biology and bioche-mistry ofascorbic acid. N Eng. J Med 1986;314:892-902.
14. 14. Barrita JLS, Sánchez MDSS. Antioxidant role of ascorbic acid and his protective effects on chronic diseases. Oxidative Stress and Chronic Degenerative Diseases-A Role for Anti-oxidants. 2013;449.
15. 15. Huijskens MJAJ, Wodzig WKWH, Walczak M, Germeraad WTV, Bos GMJ. Ascorbic acid serum levels are reduced in patients with hematological malignancies. Results Immu-nol 2016;6:8–10.
16. 16. Chen Q, Polireddy K, Chen P, Dong R. The unpaved journey of vitamin C in cancer treatment. Can. J. Physiol. Pharmacol. 2015;93(12):1055-1063
17. 17. Ngo B, Van Riper J M, Cantley L C, Yun J. Targeting cancer vulnerabilities with high-dose vitamin C. Nat Rev Cancer. 2019;19(5):271-282.
18. 18. Pawlowska E, Szczepanska J, Blasiak J. Pro-and Antioxidant Effects of Vitamin C in Cancer in correspondence to Its Die-tary and Pharmacological Concentrations. Oxid Med Cell Longev. 2019:7286737.
19. 19. Carr AC, Vissers M, Cook JS. The effect of intravenous vita-min C on cancer-and chemotherapy-related fatigue and qu-ality of life. Front Oncol. 2014;4:283.
20. 20. Battisti V, Maders LD, Bagatini MD, Barbosa NV, Battisti IDE, Belle LP, et al. Measurement of oxidative stress and antioxidant status in acute lymphoblastic leukemia pati-ents. Clin Biochem. 2008;41:511–518.
21. 21. Pawlowska E, Blasiak J. DNA repair-a double-edged sword in the genomic stability of cancer cells-the case of chronic myeloid leukemia. Int J Mol Sci. 2015;16:27535–27549.
22. 22. Chung YJ, Robert C, Gough SM, Rassool FV, Aplan PD. Oxi-dative stress leads to increased mutation frequency in a murine model of myelodysplastic syndrome. Leuk Res. 2014;38:95–102.
23. 23. Hole PS, Darley RL, Tonks A. Do reactive oxygen species play a role in myeloid leukemias? Blood. 2011;117:5816–5826.
24. 24. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World He-alth Organisation Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leuke-mia. 2022;36(7):1720-1748.
25. 25. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345-1377.
26. 26. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leuke-mia. 2022;36(7):1703-1719.
27. 27. Hutchings M, Specht L. PET/CT in the management of hae-matological malignancies. European journal of haemato-logy. 2008;80(5):369-80.
28. 28. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disea-se assessment in multiple myeloma. Lancet On-col. 2016;17:e328–46
29. 29. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, sta-ging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin On-col. 2014;32(27):3059-68.
30. 30. White R, Nonis M, Pearson JF, Rumball C, Izzard M, Wil-liams L, et al. Low Vitamin C Status in Patients With Cancer Is Associated With Patient and Tumor Characteris-tics. Nutrients. 2020;12:2338.
31. 31. Pujari KN, Jadkar SP, Mashal SN, Belwalkar GJ, Kulkarni A, Patil CG. Variations in vitamin C levels in leukemias. Bio-med Res. 2012;23:307-311
32. 32. Liua M, Ohtania H, Zhoua W, Ørskovb AD, Charletc J, Zhangd YW. Vitamin C increases viral mimicry induced by 5-aza-2′-deoxycytidine. PNAS. 2016;113:10238-10244.
33. 33. Shenoy N, Bhagat T, Nieves E, Stenson M, Lawson J, Choud-hary GS. Upregulation of TET activity with ascorbic acid in-duces epigenetic modulation of lymphoma cells. Blood Can-cer J. 2017;7:e587.
34. 34. Ottone T, Faraoni I, Fucci G, Martini M, Venditti A, Testi AM, et al. Vitamin C Deficiency in Patients With Acute Mye-loid Leukemia. Front Oncol. 2022;12:890344
35. 35. Sharma A, Tripathi M, Satyam A, Kumar L. Study of antioxidant levels in patients with multiple myeloma. Leuk Lymphoma. 2009;50(5):809-815.
36. 36. Ohno S, Ohno Y, Suzuki N, Soma G, Inoue M. High-dose vitamin C (ascorbic acid) therapy in the treatment of pati-ents with advanced cancer. Anticancer Res. 2009;29:809–815.
37. 37. Mikirova NA, Ichim TE, Riordan NH. Anti-angiogenic effect of high doses of ascorbic acid. J Transl Med. 2008;6(1):1-10.
38. 38. Klimant E, Wright H, Rubin D, Seely D. Markman M. Intra-venous vitamin C in the supportive care of cancer patients: A review and rational approach. Curr. Oncol. 2018;25:139